Strattera Drug
Eli Lilly's new drug for attention deficit hyperactivity disorder , Strattera, may have trouble getting reimbursement from HMO formularies - ADHD - Eli Lilly and Co - health maintenance organizations - Brief Article * Eli Lilly's new drug for attention deficit hyperactivity disorder (ADHD), Strattera, may have trouble getting reimbursement from HMO formularies, according to a study by Decision Resources. The drug is a latecomer to this therapeutic category, which includes some generics, and relationships between HMOs and manufacturers are fairly well-cemented. Nevertheless, psychiatrists and PCPs anticipate switching 25% of their patients to Strattera, and pediatricians plan on switching about 10%. The report is entitled "Impact of Strattera's Launch and Psychostimulant Patent Expiries," and is based on a survey of 16 HMO pharmacy directors, 43 PCPs, 36 pediatricians, and 20 psychiatrists. Strattera was approved in January 2003 and would normally be expected to appear on HMO formularies in 6-to-12 months. Strattera offers an advantage in that it is not a controlled substance like competing ADHD therapies, yet still offers once-daily dosing. Information: Elizabeth Marshall, Decision Resources, (781) 296-2563.
COPYRIGHT 2003 Atlantic Information Services, Inc.
COPYRIGHT 2003 Gale Group
|
